Fintel reports that on September 27, 2024, Leerink Partners downgraded their outlook for Agios Pharmaceuticals (NasdaqGS:AGIO ...

On Friday, Geron Corp (GERN) stock saw a modest uptick, ending the day at $4.57 which represents a slight increase of $0.14 or 3.16% from the prior close of $4.43. The stock opened at $4.47 and ...

Agios Pharmaceuticals (AGIO) stock was downgraded at Leerink Partners on Pfizer's (PFE) recent decision to withdraw sickle ...

On Friday, Ardelyx Inc (ARDX) stock saw a modest uptick, ending the day at $6.65 which represents a slight increase of $0.29 or 4.56% from the prior close of $6.36. The stock opened at $6.43 and ...

Leerink Partners analyst Faisal Khurshid said that he likes the “risk/reward” profile of Immunic’s CALLIPER trial readout, ...

In a report released on September 25, Marc Goodman from Leerink Partners maintained a Hold rating on Alkermes (ALKS – Research Report).

Leerink Partners analyst Roanna Ruiz maintained a Hold rating on Enanta Pharmaceuticals (ENTA – Research Report) yesterday. The ...

Regeneron (REGN) stock was downgraded by Leerink after a court ruling that favored Amgen's (AMGN) plans to introduce a biosimilar for REGN's Eylea. Read more here.

Equities researchers at Leerink Partners initiated coverage on shares of MannKind (NASDAQ:MNKD – Get Free Report) in a research report issued to clients and investors on Monday, Marketbeat reports.

Fintel reports that on September 24, 2024, Leerink Partners downgraded their outlook for Regeneron Pharmaceuticals (WBAG:REGN) from Outperform to Market Perform. There are 2,433 funds or ...

On Thursday, Leerink Partners sustained their optimistic stance on Celldex (NASDAQ:CLDX) Therapeutics (NASDAQ:CLDX), maintaining an Outperform rating and a $78.00 price target for the stock. The ...

Leerink Partners analyst Faisal Khurshid said that he likes the “risk/reward” profile of Immunic’s CALLIPER trial readout, expected in April 2025. Immunic hosted a Multiple Sclerosis (MS ...